Early mortality in acute myeloid leukemia

Leukemia Research
Andrew HahnMike G Martin

Abstract

The Southwest Oncology Group (SWOG) described the expected early mortality rate (EMR) for patients with non-M3 AML by age enrolled in clinical trials, but it is unclear how generalizable this data is. We sought to compare SWOG's reported EMR to that of the general population by utilizing the case listing session of SEER 18 matched to the accrual periods of the SWOG studies. 26,272 patients were identified within SEER compared to 968 in the SWOG cohort with mortality data. The EMR was 26.7% (7022 events) in the SEER cohort versus 12.2% (116) in the SWOG cohort. The EMR was higher in the SEER cohort in every studied age group and definition of EMR. Stepwise logistic regression analysis identified increasing age, black race (OR 1.15, CI 1.03-1.29, p<0.01), and monocytic differentiation (OR 1.55, CI 1.27-1.89, p<0.01) as predictors of higher EMR. This study demonstrates that EMR in patients with non-M3 AML is higher in the general patient population than reported in SWOG clinical trials.

References

Nov 9, 2000·Leukemia·F LeviC La Vecchia
Feb 19, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin S TallmanUNKNOWN Eastern Cooperative Oncology Group
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Oct 5, 2006·Cancer·Barbara Deschler, Michael Lübbert
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterElihu H Estey
Mar 3, 2012·Blood·Gunnar JuliussonUNKNOWN Swedish Acute Leukemia Registry Group
Jul 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O VisserUNKNOWN RARECARE Working Group
Sep 18, 2012·Haematologica·Marc MaynadiéUNKNOWN HAEMACARE Working Group
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Aug 1, 2015·Blood Reviews·Andrew W HahnMike G Martin
Sep 21, 2015·Clinical Lymphoma, Myeloma & Leukemia·Andrew W HahnMike G Martin
Oct 28, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kuang-Hsi ChangChieh-Lin Jerry Teng
Nov 12, 2016·Clinical Lymphoma, Myeloma & Leukemia·Syed Sameer NasirMike G Martin
Jun 5, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew H WeiHagop M Kantarjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.